Axogen, Inc. (AXGN) News
Follow Axogen, Inc. (AXGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 32 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Analysts Raise Price Targets for Axogen After Q3 Results
Truist and Barclays lifted Axogen price targets to $60, from $53 and $50, respectively; Wells Fargo raised its target to $56 from $48. Truist and Barclays maintained Buy ratings.
EQUITY | Oct 29, 2026, 06:03 PM UTC
M
AXGN Reports Fiscal Q3 Shareholder Net Loss
AXGN reported a fiscal third-quarter net loss attributable to shareholders, down 636.79% year over year, and basic EPS was negative.
EQUITY | Oct 29, 2026, 07:45 AM UTC
M
AxoGen shares surge after upbeat annual revenue outlook
EQUITY | Oct 28, 2026, 03:39 PM UTC
M
AxoGen Reports Results for Quarter Ended September 30
EARNINGS | Oct 28, 2026, 02:09 PM UTC
M
Axogen Shares Rise 22% After Third-Quarter Revenue and Earnings Beat Expectations
Axogen reported third-quarter revenue and earnings above analysts’ expectations. Its shares rose 22% to $45.61 in morning trading.
EARNINGS | Oct 28, 2026, 02:04 PM UTC
M
Axogen Raises 2026 Revenue Guidance as Q3 Income and Revenue Increase
Axogen shares rose more than 21% in early trading, according to MT Newswires.
EQUITY | Oct 28, 2026, 01:36 PM UTC
M
Axogen Expects 2026 Revenue of at Least $290M in 2026
Axogen expects 2026 revenue of at least $290 million, versus a FactSet estimate of $283.8 million.
EARNINGS | Oct 28, 2026, 11:22 AM UTC
M
Axogen Q3 Adjusted EPS $0.21 vs. IBES Estimate $0.14
Axogen reported Q3 adjusted EPS of $0.21, compared with the IBES estimate of $0.14.
EARNINGS | Oct 28, 2026, 11:19 AM UTC
M
Axogen Q3 Net Income More Than Triples to $2.33 Million
Q3 revenue rose 26% year over year to $75.83 million.
EQUITY | Oct 28, 2026, 11:17 AM UTC
M
AxoGen Q3 Revenue Beats Estimates
EQUITY | Oct 28, 2026, 11:13 AM UTC
M
Axogen Shares Rise 8.1% Premarket After Revenue Forecast
Axogen shares rose 8.1% premarket after the company forecast full-year revenue above estimates.
EARNINGS | Oct 28, 2026, 11:10 AM UTC
M
Axogen Sees 2026 Revenue at Least $290M
EARNINGS | Oct 28, 2026, 11:07 AM UTC
M
AxoGen Q3 Revenue Reaches $75.8 Million
AxoGen reported Q3 revenue of $75.8 million, compared with the IBES estimate of $73.2 million.
EQUITY | Oct 28, 2026, 11:07 AM UTC
M
Axogen Reports Third-Quarter 2026 Financial Results
EQUITY | Oct 28, 2026, 11:07 AM UTC
M
Axogen reports third-quarter adjusted EBITDA of $13.4 million
EARNINGS | Oct 28, 2026, 11:07 AM UTC
M
Axogen Reports Q3 Gross Margin of 74.8%
EARNINGS | Oct 28, 2026, 11:06 AM UTC
M
Axogen to report third-quarter 2026 results October 28
EQUITY | Oct 14, 2026, 11:00 AM UTC
L
Axogen Price Target Raised to $53.00/Share From $48.00 by Raymond James
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 12:40 PM UTC
H
Axogen to acquire BioCircuit for $200 million in cash
Axogen Inc. agreed to acquire BioCircuit Technologies Inc. for $200 million in cash, integrating NerveTape into its surgical solutions. To finance the purchase, it launched an underwritten public offering of 4.91 million
MNA | Sep 10, 2026, 04:31 PM UTC
L
Axogen $200 million acquisition adds NerveTape to portfolio
Axogen, Inc. is acquiring BioCircuit for $200 million, bringing NerveTape—a high-growth, FDA-approved nerve repair device—into the portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027.
EARNINGS | Sep 10, 2026, 01:18 PM UTC
L
AXGN to buy BioCircuit for $200 million cash acquisition
AXGN will pay $200 million in cash to acquire BioCircuit, adding NerveTape and an FDA-approved suture-less nerve repair device to its portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027.
EARNINGS | Sep 10, 2026, 12:52 PM UTC
L
AXGN to buy an FDA-cleared sutureless nerve repair for $200M cash
Axogen said it will acquire a differentiated, FDA-cleared sutureless nerve repair device. The $200M cash deal is expected to be accretive to revenue and margins in Year 1, with closing expected in Q4 2026.
EARNINGS | Sep 10, 2026, 11:27 AM UTC
H
Axogen to buy BioCircuit Technologies for $200M in cash
Axogen, NASDAQ:AXGN, has agreed to acquire privately held medical-device company BioCircuit Technologies for $200M in cash. The company plans to fund the purchase price with net proceeds from a concurrent public offer.
MNA | Sep 10, 2026, 11:11 AM UTC
L
Axogen: Deal Adds NerveTape Device for Sutureless Peripheral Nerve Repair >AXGN
Axogen: Deal Adds NerveTape Device for Sutureless Peripheral Nerve Repair >AXGN
EQUITY | Sep 10, 2026, 10:16 AM UTC
L
Axogen enters definitive agreement to acquire BioCircuit Technologies
Axogen Enters Into Definitive Agreement To Acquire BioCircuit Technologies >AXGN
MNA | Sep 10, 2026, 10:04 AM UTC
M
Axogen prices $208.7 million public common stock offering
EQUITY | Sep 10, 2026, 10:01 AM UTC
L
Axogen management to meet investors at Morgan Stanley healthcare conference
Axogen said management will be available for one-on-one investor meetings at the 24th Annual Morgan Stanley Global Healthcare Conference.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
Axogen to participate in Morgan Stanley Global Healthcare conference
Axogen, Inc. will participate in the 24th Annual Morgan Stanley Global Healthcare Conference.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
AXGN Axogen RESULTS: Q2, Q2 REV $69.7M vs. EST $67.1M, Q2 gross margin 72.7%, Q2 ADJ EBITDA $8.4M, Q2 ADJ Net Income $7.3M, Q2 Net Income $
AXGN Axogen RESULTS: Q2, Q2 REV $69.7M vs. EST $67.1M, Q2 gross margin 72.7%, Q2 ADJ EBITDA $8.4M, Q2 ADJ Net Income $7.3M, Q2 Net Income $-1.5M, Q2 ADJ EPS $0.12 vs. EST $0.12, Axogen Earnings Notes:, Outlook FY REV $27
EARNINGS | Jul 29, 2026, 11:07 AM UTC
L
AXGN - Axogen, Inc. Reports Second Quarter 2026 Financial Results
AXGN - Axogen, Inc. Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 11:05 AM UTC
L
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - CAR, ASH, TLRY, PDM, BRSP, TRTX, PDS, TTAM, NO
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - CAR, ASH, TLRY, PDM, BRSP, TRTX, PDS, TTAM, NOV, MEOH, AAT, SW, AXGN
EARNINGS | Jul 28, 2026, 04:09 PM UTC
L
STIM AXGN Neuronetics appoints nir naor Chief Financial Officer; announces additional management changes
STIM AXGN Neuronetics appoints nir naor Chief Financial Officer; announces additional management changes
EQUITY | Jul 20, 2026, 08:05 PM UTC